EIF2AK4 and hepatocellular carcinoma: Another study showed that aberrant expression of four key RBPs, including mitochondrial ribosomal protein L54 (MRPL54), enhancer of zeste homolog 2 (EZH2), PPARγ coactivator 1 alpha (PPARGC1A), and eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4), can be applied to HCC prognosis [100].